drugset / Trial / NCT05381662
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment
Phase 1/2
Unknown
10 enrolled
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
The First Affiliated Hospital of Soochow University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors combined with CD19 positive feeder T cells treatment for CD19+ acute lymphoblastic leukemia patients in remission .
Timeline
- Start
- 2018-08-02
- Primary completion
- 2024-08-02
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | — | — |
| Subject | CD19 positive feeder T cells | Cell therapy | — | — |